Tatas, Marmilyn A.
HRN: 22-36-76 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/27/2023
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
11/27/2023
12/04/2023
IV
1.5
Q8
Breast Mass Infection
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes